Gevo Inc

GEVO remains entrenched in a Stage 4 decline with a clear lower-high/ lower-low sequence under declining EMAs. The recent oversold bounce stalled at the 9- and 21-EMA resistance zone, showing no sustained follow-through and leaving price extended into overhead supply. Medium-term bias is bearish; the optimal posture is to sell into strength at failed tests of these moving averages. Primary risks include a decisive breakout above the EMAs signaling a reversal or the development of a consolidation base that stabilizes price.

• ↑Revenue $161 M in FY25 (849% YoY growth) from ATJ integration
• ↑Q1 26 non-GAAP adj EBITDA $9 M vs. $15 M loss a year ago
• ↓Earnings yield negative and Q1 26 net loss $22 M signals weak profitability